Aseptuva raises $2.4M Seed (Switzerland, Sep 2026)
Reach the investors backing rounds like this
Backed by Simon Michel, Roger Nitsch +5 more · verified emails and LinkedIn on Datapile
Following a CHF 2.4 million seed round, Aseptuva progressed to preclinical validation - Startupticker.ch
Aseptuva is a Swiss-UK Medtech startup developing a targeted Far-UVC disinfection technology to prevent hospital-acquired infections, particularly bloodstream infections associated with intravenous catheters. Their technology aims to reduce infection risk and antibiotic reliance by disinfecting at the catheter-entry site. The company is focused on preventing deaths, shortening hospital stays, and reducing healthcare costs.
Following a CHF 2.4 million seed round, Aseptuva progressed to preclinical validation Startupticker.ch
| Sep 15, 2026 | Kaiko | $110.0M | Series B | Switzerland |
| Sep 14, 2026 | Aware Health | $12.0M | Seed | Switzerland |
| Sep 01, 2026 | xorlab | $5.3M | Series A+ | Switzerland |
| Aug 31, 2026 | KOVE medical | $1.8M | Seed | Switzerland |
11,942 investors back startups in Switzerland
You just read who funded Aseptuva. The same database has the investors behind every other round — with verified emails, check sizes and the stages they actually write at.
Free account: 15 investor contact unlocks a month, no card required.